O MedHeed é uma plataforma alimentada por IA para profissionais de saúde, projetada para acelerar a pesquisa médica e a tomada de decisões clínicas. Ele usa PNL avançada para analisar e sintetizar grandes volumes de literatura médica, dados de ensaios clínicos e diretrizes de tratamento, fornecendo aos usuários insights selecionados e baseados em evidências em tempo real.
Rayyan é uma plataforma alimentada por IA projetada para pesquisadores acelerarem revisões sistemáticas e de literatura. Ela otimiza o processo com recursos como triagem automatizada, detecção de duplicatas e colaboração em tempo real, economizando até 90% do tempo de triagem dos pesquisadores. Com a confiança de mais de 800.000 usuários, ela suporta todo o ciclo de vida da revisão, desde a importação de dados até o relatório final.
Visão geral
MedHeed Visão geral
O MedHeed é uma plataforma alimentada por IA para profissionais de saúde, projetada para acelerar a pesquisa médica e a tomada de decisões clínicas. Ele usa PNL avançada para analisar e sintetizar grandes volumes de literatura médica, dados de ensaios clínicos e diretrizes de tratamento, fornecendo aos usuários insights selecionados e baseados em evidências em tempo real.
Rayyan Visão geral
Rayyan é uma plataforma alimentada por IA projetada para pesquisadores acelerarem revisões sistemáticas e de literatura. Ela otimiza o processo com recursos como triagem automatizada, detecção de duplicatas e colaboração em tempo real, economizando até 90% do tempo de triagem dos pesquisadores. Com a confiança de mais de 800.000 usuários, ela suporta todo o ciclo de vida da revisão, desde a importação de dados até o relatório final.
Detailed feature comparison
| Feature | MedHeed | Rayyan |
|---|---|---|
| Categoria principal | Pesquisa Médica | Acadêmico |
| Adicionado | 2025-08-14 | 2025-09-11 |
| Preço | Freemium | Freemium |
| Site oficial | medheed.co | rayyan.ai |
| Tipo de produto | Site | Site |
| Performance data | ||
| Avaliação | Não verificado | Não verificado |
| Comentários | 0 | 0 |
| Visitas mensais | 3.4K | 1.1M |
| Crescimento mensal | Não verificado | -4% |
| Favoritos | 134 | 128 |
| Details | Ver detalhes | Ver detalhes |
MedHeed vs Rayyan monthly traffic
Compare MedHeed and Rayyan by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
MedHeed monthly traffic:
Latest traffic
Rayyan monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 917.4K Visitas mensais
- 2026/1: 942.9K Visitas mensais
- 2026/2: 1M Visitas mensais
- 2026/3: 1.1M Visitas mensais
- 2026/4: 1.1M Visitas mensais
- 2026/5: 1.1M Visitas mensais
Principais regiões
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 32.99% | 359.1K |
| 🇧🇷Brazil | 31.2% | 339.6K |
| 🇬🇧United Kingdom | 20.31% | 221K |
| 🇵🇰Pakistan | 7.75% | 84.3K |
| 🇵🇹Portugal | 7.75% | 84.3K |
Fontes de tráfego
| Source type | Percentage | Traffic |
|---|---|---|
| Direto | 80.86% | 880.1K |
| Referência | 14.66% | 159.6K |
| 4.48% | 48.8K |
Palavras-chave
Usage comparison
Compare the core capabilities of MedHeed and Rayyan
MedHeed Core features
Rayyan Core features
Use cases
MedHeed Use cases
Rayyan Use cases
Best suited roles
MedHeed Best suited roles
Rayyan Best suited roles
MedHeed vs Rayyan:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth MedHeed vs Rayyan comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. MedHeed is primarily listed under “Pesquisa Médica”, while Rayyan is primarily listed under “Acadêmico”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (MedHeed: Pesquisa Médica; Rayyan: Acadêmico); Monthly visits (MedHeed: 3.4K; Rayyan: 1.1M); Favorites (MedHeed: 134; Rayyan: 128); Website (MedHeed: medheed.co; Rayyan: rayyan.ai); Added (MedHeed: 2025-08-14; Rayyan: 2025-09-11). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Product positioning, use cases, and roles
MedHeed and Rayyan currently overlap in shared categories: Pesquisa; shared tags: análise de dados, revisão da literatura e pesquisa médica. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
MedHeed's unique categories/tags are Pesquisa Médica, Ensaios clínicos, Descoberta de medicamentos, medicina baseada em evidências, IA na saúde e Tecnologia da saúde; Rayyan's are Acadêmico, Triagem por IA, Colaboração, Desduplicação, Prisma, Pesquisa, Escrita científica e Revisão sistemática. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
MedHeed has no verified rating, 0 comments, 134 favorites, and 122 likes;Rayyan has no verified rating, 0 comments, 128 favorites, and 116 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate MedHeed first
Put MedHeed on the priority trial list when the task aligns with “Pesquisa Médica” and especially Pesquisa Médica, Ensaios clínicos, Descoberta de medicamentos, medicina baseada em evidências, IA na saúde e Tecnologia da saúde. This follows recorded positioning and does not imply unlisted capabilities are absent.
MedHeed also currently records: pricing is freemium, product type is website, 3.4K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate Rayyan first
Put Rayyan on the priority trial list when the task aligns with “Acadêmico” and especially Acadêmico, Triagem por IA, Colaboração, Desduplicação, Prisma e Pesquisa, or the users include Acadêmico, Analista de Dados, bibliotecário e Profissional de saúde. This follows recorded positioning and does not imply unlisted capabilities are absent.
Rayyan also currently records: pricing is freemium, product type is website, 1.1M verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in MedHeed and Rayyan, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




